SpecGx LLC has secured an FDA approval for the generic version of Acetaminophen and Codeine Phosphate oral tablets, expected to expand its current portfolio and enhance its footprint in the analgesic market. The 2001-vintage ANDA for Acetaminophen and Codeine Phosphate 300-30 mg signals SpecGx’s continued focus on generics with established therapeutic profiles targeting pain management.